Meeder Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.71M | Buy |
6,094
+671
| +12% | +$514K | 0.27% | 78 |
|
|
2025
Q4 | $4.19M | Buy |
5,423
+893
| +20% | +$606K | 0.23% | 78 |
|
|
2025
Q3 | $2.55M | Sell |
4,530
-1,106
| -20% | -$625K | 0.15% | 91 |
|
|
2025
Q2 | $2.96M | Buy |
5,636
+5,616
| +28,080% | +$3.13M | 0.18% | 85 |
|
|
2025
Q1 | $12.7K | Sell |
20
-10
| -33% | -$6.88K | ﹤0.01% | 605 |
|
|
2024
Q4 | $21.4K | Sell |
30
-174
| -85% | -$146K | ﹤0.01% | 518 |
|
|
2024
Q3 | $214K | Buy |
204
+177
| +656% | +$197K | 0.01% | 215 |
|
|
2024
Q2 | $28.4K | Sell |
27
-214
| -89% | -$207K | ﹤0.01% | 446 |
|
|
2024
Q1 | $232K | Buy |
+241
| New | +$229K | 0.01% | 288 |
|
|
2023
Q3 | – | Sell |
-16
| Closed | -$11.5K | – | 570 |
|
|
2023
Q2 | $11.5K | Sell |
16
-4,811
| -100% | -$3.71M | ﹤0.01% | 441 |
|
|
2023
Q1 | $3.97M | Sell |
4,827
-33
| -0.7% | -$24.9K | 0.32% | 78 |
|
|
2022
Q4 | $3.51M | Sell |
4,860
-1,212
| -20% | -$894K | 0.31% | 84 |
|
|
2022
Q3 | $4.18M | Sell |
6,072
-1,021
| -14% | -$643K | 0.24% | 85 |
|
|
2022
Q2 | $4.19M | Buy |
7,093
+610
| +9% | +$397K | 0.24% | 80 |
|
|
2022
Q1 | $4.53M | Sell |
6,483
-8,108
| -56% | -$5.13M | 0.22% | 86 |
|
|
2021
Q4 | $9.21M | Sell |
14,591
-2,192
| -13% | -$1.35M | 0.93% | 21 |
|
|
2021
Q3 | $10.2M | Buy |
16,783
+1,565
| +10% | +$972K | 0.53% | 42 |
|
|
2021
Q2 | $8.5M | Sell |
15,218
-1,860
| -11% | -$942K | 0.4% | 59 |
|
|
2021
Q1 | $8.08M | Buy |
17,078
+16,682
| +4,213% | +$8.12M | 0.41% | 50 |
|
|
2020
Q4 | $191K | Sell |
396
-4,429
| -92% | -$2.39M | 0.04% | 317 |
|
|
2020
Q3 | $2.7M | Buy |
4,825
+64
| +1% | +$38.8K | 0.17% | 105 |
|
|
2020
Q2 | $2.97M | Sell |
4,761
-9
| -0.2% | -$5.11K | 0.19% | 104 |
|
|
2020
Q1 | $2.33M | Sell |
4,770
-5,102
| -52% | -$2.1M | 0.18% | 112 |
|
|
2019
Q4 | $3.71M | Buy |
9,872
+9,204
| +1,378% | +$3.1M | 0.23% | 101 |
|
|
2019
Q3 | $185K | Sell |
668
-369
| -36% | -$109K | 0.01% | 616 |
|
|
2019
Q2 | $325K | Sell |
1,037
-13,279
| -93% | -$4.42M | 0.02% | 477 |
|
|
2019
Q1 | $5.88M | Buy |
14,316
+1,341
| +10% | +$552K | 0.46% | 65 |
|
|
2018
Q4 | $4.85M | Buy |
12,975
+4,858
| +60% | +$1.78M | 0.43% | 64 |
|
|
2018
Q3 | $3.28M | Buy |
8,117
+6,426
| +380% | +$2.45M | 0.25% | 102 |
|
|
2018
Q2 | $583K | Buy |
1,691
+799
| +90% | +$250K | 0.05% | 340 |
|
|
2018
Q1 | $307K | Sell |
892
-567
| -39% | -$197K | 0.03% | 399 |
|
|
2017
Q4 | $549K | Sell |
1,459
-1,661
| -53% | -$673K | 0.05% | 334 |
|
|
2017
Q3 | $1.4M | Buy |
3,120
+1,812
| +139% | +$862K | 0.15% | 165 |
|
|
2017
Q2 | $642K | Buy |
+1,308
| New | +$572K | 0.06% | 318 |
|
|
2016
Q4 | – | Sell |
-217
| Closed | -$87K | – | 1040 |
|
|
2016
Q3 | $87K | Buy |
+217
| New | +$87K | 0.01% | 613 |
|
|
2016
Q2 | – | Sell |
-352
| Closed | -$127K | – | 943 |
|
|
2016
Q1 | $127K | Sell |
352
-622
| -64% | -$256K | 0.01% | 665 |
|
|
2015
Q4 | $529K | Buy |
+974
| New | +$528K | 0.05% | 311 |
|
Other funds holding REGN
VCM
N
Meeder Asset Management's REGN Position: Q1 2026 in Review
Meeder Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 12% in Q1 2026, buying an estimated $514K and bringing the position to 6,094 shares worth $4.71M. The position accounts for 0.27% of the portfolio, ranked #78.
Meeder Asset Management first reported a position in REGN in Q4 2015 and has held it in 37 quarters since. The position peaked at $10.2M in Q3 2021. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Meeder Asset Management held 6,094 shares of Regeneron Pharmaceuticals worth $4.71M as of Q1 2026.
- Meeder Asset Management bought 671 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $514K.
- Regeneron Pharmaceuticals made up 0.27% of Meeder Asset Management's portfolio in Q1 2026, its #78 holding.
- Meeder Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 37 quarters since.
- Meeder Asset Management's Regeneron Pharmaceuticals position peaked at $10.2M in Q3 2021.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.